# Jain Dataset - ELISA-based Fragments (SSOT)
# Source: test_datasets/jain/processed/jain_with_private_elisa_FULL.csv
# Labeling: ELISA flags (0→specific, 1-3→mild, ≥4→non-specific)
# Distribution: 94 specific / 22 non-specific / 21 mild
# Generated: 2025-11-06
# Script: preprocessing/jain/step3_extract_fragments.py
id,sequence,label,elisa_flags,source
abituzumab,INPRSGYT,0.0,0,jain2017_pnas
abrilumab,FDPQDGET,0.0,0,jain2017_pnas
adalimumab,ITWNSGHI,0.0,0,jain2017_pnas
alemtuzumab,IRDKAKGYTT,0.0,0,jain2017_pnas
alirocumab,ISGSGGTT,0.0,0,jain2017_pnas
anifrolumab,IYPGDSDI,0.0,0,jain2017_pnas
atezolizumab,ISPYGGST,0.0,0,jain2017_pnas
bapineuzumab,IRSGGGRT,0.0,0,jain2017_pnas
basiliximab,IYPGNSDT,0.0,0,jain2017_pnas
bavituximab,IDPYYGDT,0.0,0,jain2017_pnas
belimumab,IIPMFGTA,1.0,6,jain2017_pnas
benralizumab,INPYNDGT,0.0,0,jain2017_pnas
bevacizumab,INTYTGEP,0.0,0,jain2017_pnas
bimagrumab,INPVSGST,0.0,0,jain2017_pnas
blosozumab,SDPEIGDT,1.0,6,jain2017_pnas
bococizumab,ISPFGGRT,1.0,6,jain2017_pnas
brentuximab,IYPGSGNT,,3,jain2017_pnas
briakinumab,IRYDGSNK,1.0,4,jain2017_pnas
brodalumab,ISTYSGNT,,1,jain2017_pnas
canakinumab,IWYDGDNQ,0.0,0,jain2017_pnas
carlumab,IIPIFGTA,1.0,4,jain2017_pnas
certolizumab,INTYIGEP,0.0,0,jain2017_pnas
cetuximab,IWSGGNT,0.0,0,jain2017_pnas
cixutumumab,IIPIFGTA,1.0,6,jain2017_pnas
clazakizumab,IYGSDET,0.0,0,jain2017_pnas
codrituzumab,LDPKTGDT,1.0,6,jain2017_pnas
crenezumab,INSNGGST,0.0,0,jain2017_pnas
dacetuzumab,VIPNAGGT,0.0,0,jain2017_pnas
daclizumab,INPSTGYT,,1,jain2017_pnas
dalotuzumab,ISYDGTN,1.0,5,jain2017_pnas
daratumumab,ISGSGGGT,0.0,0,jain2017_pnas
denosumab,ITGSGGST,1.0,5,jain2017_pnas
dinutuximab,IDPYYGGT,0.0,0,jain2017_pnas
drozitumab,INWQGGST,0.0,0,jain2017_pnas
duligotuzumab,ISAAGGYT,1.0,6,jain2017_pnas
dupilumab,ISGSGGNT,1.0,5,jain2017_pnas
eculizumab,ILPGSGST,0.0,0,jain2017_pnas
efalizumab,IHPSDSET,0.0,0,jain2017_pnas
eldelumab,IWFDGMNK,0.0,0,jain2017_pnas
elotuzumab,INPDSSTI,0.0,0,jain2017_pnas
emibetuzumab,VNPNRRGT,1.0,6,jain2017_pnas
enokizumab,ILPGSGTT,0.0,0,jain2017_pnas
epratuzumab,INPRNDYT,,1,jain2017_pnas
etrolizumab,ISYSGST,,2,jain2017_pnas
evolocumab,VSFYNGNT,,2,jain2017_pnas
farletuzumab,ISSGGSYT,0.0,0,jain2017_pnas
fasinumab,FDPEDGET,0.0,0,jain2017_pnas
fezakinumab,INPYTGSA,0.0,0,jain2017_pnas
ficlatuzumab,INPTNGHT,0.0,0,jain2017_pnas
figitumumab,ISGSGGTT,,3,jain2017_pnas
fletikumab,INAGYGNT,0.0,0,jain2017_pnas
foralumab,IWYDGSKK,,2,jain2017_pnas
fresolimumab,VIPIVDIA,0.0,0,jain2017_pnas
fulranumab,ISRSSHTI,,1,jain2017_pnas
galiximab,FYSSSGNT,0.0,0,jain2017_pnas
ganitumab,IYHSGST,0.0,0,jain2017_pnas
gantenerumab,INASGTRT,1.0,6,jain2017_pnas
gemtuzumab,IYPYNGGT,0.0,0,jain2017_pnas
gevokizumab,IWWDGDE,0.0,0,jain2017_pnas
girentuximab,INSDGGIT,0.0,0,jain2017_pnas
glembatumumab,IYYSGST,0.0,0,jain2017_pnas
golimumab,MSYDGSNK,,1,jain2017_pnas
guselkumab,IDPSNSYT,,1,jain2017_pnas
ibalizumab,INPYNDGT,0.0,0,jain2017_pnas
imgatuzumab,FNPNSGYS,1.0,5,jain2017_pnas
infliximab,IRSKSINSAT,0.0,0,jain2017_pnas
inotuzumab,INPGNNYA,,3,jain2017_pnas
ipilimumab,ISYDGNNK,0.0,0,jain2017_pnas
ixekizumab,INPMYGTT,1.0,6,jain2017_pnas
lampalizumab,INTYTGET,0.0,0,jain2017_pnas
lebrikizumab,IWGDGKI,0.0,0,jain2017_pnas
lenzilumab,INAGNGNT,1.0,6,jain2017_pnas
lintuzumab,IYPYNGGT,0.0,0,jain2017_pnas
lirilumab,FIPIFGAA,0.0,0,jain2017_pnas
lumiliximab,ISSSGDPT,0.0,0,jain2017_pnas
matuzumab,FNPSNGRT,0.0,0,jain2017_pnas
mavrilimumab,FDPEENEI,0.0,0,jain2017_pnas
mepolizumab,IWASGGT,0.0,0,jain2017_pnas
mogamulizumab,ISSASTYS,0.0,0,jain2017_pnas
motavizumab,IWWDDKK,,1,jain2017_pnas
muromonab,INPSRGYT,0.0,0,jain2017_pnas
natalizumab,IDPANGYT,0.0,0,jain2017_pnas
necitumumab,IYYSGST,0.0,0,jain2017_pnas
nimotuzumab,INPTSGGS,0.0,0,jain2017_pnas
nivolumab,IWYDGSKR,0.0,0,jain2017_pnas
obinutuzumab,IFPGDGDT,0.0,0,jain2017_pnas
ocrelizumab,IYPGNGDT,0.0,0,jain2017_pnas
ofatumumab,ISWNSGSI,0.0,0,jain2017_pnas
olaratumab,FFYTGST,0.0,0,jain2017_pnas
olokizumab,MRNKNYQYGT,0.0,0,jain2017_pnas
omalizumab,ITYDGST,0.0,0,jain2017_pnas
onartuzumab,IDPSNSDT,0.0,0,jain2017_pnas
otelixizumab,ISTSGGRT,0.0,0,jain2017_pnas
otlertuzumab,IDPYYGGT,0.0,0,jain2017_pnas
ozanezumab,INPSNGGT,,3,jain2017_pnas
palivizumab,IWWDDKK,0.0,0,jain2017_pnas
panitumumab,IYYSGNT,0.0,0,jain2017_pnas
panobacumab,INSDGST,0.0,0,jain2017_pnas
parsatuzumab,INLDNSGT,1.0,6,jain2017_pnas
patritumab,INHSGST,1.0,4,jain2017_pnas
pembrolizumab,INPSNGGT,0.0,0,jain2017_pnas
pertuzumab,VNPNSGGS,0.0,0,jain2017_pnas
pinatuzumab,IYPGDGDT,0.0,0,jain2017_pnas
polatuzumab,ILPGGGDT,0.0,0,jain2017_pnas
ponezumab,IDPATGNT,1.0,4,jain2017_pnas
radretumab,ISGSSGTT,0.0,0,jain2017_pnas
ramucirumab,ISSSSSYI,0.0,0,jain2017_pnas
ranibizumab,INTYTGEP,,1,jain2017_pnas
reslizumab,IWSNGDT,0.0,0,jain2017_pnas
rilotumumab,VYYSGST,0.0,0,jain2017_pnas
rituximab,IYPGNGDT,0.0,0,jain2017_pnas
robatumumab,IDTRGAT,1.0,4,jain2017_pnas
romosozumab,INPNSGGA,0.0,0,jain2017_pnas
sarilumab,ISWNSGRI,0.0,0,jain2017_pnas
secukinumab,INQDGSEK,0.0,0,jain2017_pnas
seribantumab,ISSSGGWT,0.0,0,jain2017_pnas
sifalimumab,ISVYNGNT,,3,jain2017_pnas
siltuximab,ISSGGSYT,0.0,0,jain2017_pnas
simtuzumab,INPGSGGT,1.0,6,jain2017_pnas
sirukumab,ISPGGSWT,1.0,5,jain2017_pnas
tabalumab,INHSGST,0.0,0,jain2017_pnas
tanezumab,IWGDGTT,,1,jain2017_pnas
teplizumab,INPSRGYT,,2,jain2017_pnas
tigatuzumab,ISSGGSYT,0.0,0,jain2017_pnas
tildrakizumab,IFPASGSA,0.0,0,jain2017_pnas
tocilizumab,ISYSGIT,0.0,0,jain2017_pnas
tovetumab,ISSSGSII,0.0,0,jain2017_pnas
tralokinumab,ISANNGDT,0.0,0,jain2017_pnas
trastuzumab,IYPTNGYT,0.0,0,jain2017_pnas
tremelimumab,IWYDGSNK,0.0,0,jain2017_pnas
urelumab,INHGGYV,0.0,0,jain2017_pnas
ustekinumab,MSPVDSDI,,3,jain2017_pnas
vedolizumab,IDPSESNT,0.0,0,jain2017_pnas
veltuzumab,IYPGMGDT,0.0,0,jain2017_pnas
visilizumab,INPRSGYT,,3,jain2017_pnas
zalutumumab,IWDDGSYK,,1,jain2017_pnas
zanolimumab,INHSGST,0.0,0,jain2017_pnas
